Tris Pharma previously announced data from another Phase III trial of cebranopadol, which also met its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback